Core Viewpoint - The article discusses the performance of stocks categorized as "猛兽股" (beast stocks), focusing on those with a price increase of over 4 times within a year, and highlights the emergence of two distinct trading patterns: the traditional trend model and the volume accumulation model [1][2]. Group 1: Stock Selection Criteria - The selection formula for identifying beast stocks is based on a specific calculation involving the highest high and lowest low over a defined period [1]. - A total of 99 stocks were identified in the market, with 40 stocks filtered through an earnings pre-selection pool, although the specific list is not provided [2]. Group 2: Market Trends and Patterns - The current bull market has seen a significant increase in the volume accumulation model, with a ratio of approximately 6:4 compared to the traditional model [2]. - The volume accumulation model results in steeper price increase slopes and shorter time frames for achieving similar gains, with some stocks completing significant price movements in just days or weeks [2]. - The rise of quantitative trading is closely linked to the volume accumulation model, which emphasizes high-frequency trading and rapid turnover, previously dominated by speculative funds [2]. Group 3: Differences Between Trading Models - The traditional trend model is closely tied to earnings growth, while the volume accumulation model shows little correlation with earnings performance [2][5]. - Stocks selected under the traditional model are fundamentally different from those in the volume accumulation model, reflecting divergent views on the importance of fundamentals versus short-term market sentiment [4][5]. Group 4: Commonalities and Market Implications - Both trading models exhibit a common principle of minimal drawdowns during trends, with only a small fraction of the selected stocks experiencing significant pullbacks [5]. - The average drawdown for potential bull stocks in 2025 is lower than in previous years, theoretically making it easier to hold positions [5]. - The emergence of the volume accumulation model presents both challenges and opportunities for investors, suggesting a need for diversification in investment strategies [5].

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]

Group 1 - The chemical pharmaceutical sector experienced a decline of 0.31% on December 31, with Xintai leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] - Key stocks in the chemical pharmaceutical sector showed varied performance, with Jinling Pharmaceutical rising by 5.58% and Xintai falling by 4.33% [1][2] Group 2 - The total net outflow of main funds in the chemical pharmaceutical sector was 892 million yuan, while retail investors saw a net inflow of 759 million yuan [2] - The top stocks by net inflow included Xingqi Eye Medicine with 74.40 million yuan and Huadong Pharmaceutical with 68.23 million yuan [3] - Notable stocks like Hongyuan Pharmaceutical and Aoxiang Pharmaceutical also saw significant net inflows from main funds [3]

Group 1 - The core viewpoint of the news is that 海思科 (Haisco) has shown a slight increase in stock price, reaching 51.14 yuan per share, with a total market capitalization of 57.273 billion yuan as of December 31 [1] - 海思科's main business involves the research, development, production, and sales of chemical pharmaceuticals, with revenue composition as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other (supplementary) 0.86% [1] Group 2 - 中欧医疗健康混合A (China Europe Medical Health Mixed A) fund has increased its holdings in 海思科 by 121,200 shares, bringing its total to 21,397,500 shares, which accounts for 4.44% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.6% and a one-year return of 11.58%, ranking 5,297 out of 8,085 in its category [2] Group 3 - The fund manager of 中欧医疗健康混合A is 葛兰 (Gelan) and 赵磊 (Zhao Lei), with total fund assets of 435.44 billion yuan and 329.54 billion yuan respectively [3] - 葛兰 has a tenure of 10 years and 340 days, with the best fund return of 97.86% and the worst return of -35.13% during her tenure [3] Group 4 - 中欧医疗健康混合A has 海思科 as its tenth largest holding, representing 3.47% of the fund's net value, with a floating profit of approximately 11.1267 million yuan [4]

Core Viewpoint - The company, Borui Pharmaceutical, reported a stock price of 49.4 yuan as of December 30, 2025, with a slight decline of 0.66% and a trading volume of 41,400 shares, amounting to a total transaction value of 205 million yuan [1]. Trading Information Summary - On December 30, the main funds experienced a net outflow of 20.59 million yuan, accounting for 10.03% of the total transaction value; retail investors saw a net inflow of 12.39 million yuan, representing 6.04% of the total [2]. - The company’s stock trading saw a turnover rate of 0.98% [1]. Company Announcements Summary - The underwriting and sponsoring company, Guolian Minsheng Securities, conducted an on-site inspection of Borui Pharmaceutical for its 2025 annual continuous supervision work, confirming that the company has a sound governance structure and complies with regulations regarding fundraising and investment [2]. - The board of directors approved a proposal to postpone the expected operational status date for several fundraising projects to March 2027, due to pending product approvals and the need for additional construction of an automated warehouse [2][3]. Internal Governance and Audit - Borui Pharmaceutical established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities, with regular reporting to the audit committee [4]. - The company also implemented a foreign exchange trading management system to mitigate exchange rate risks and ensure the safety of funds, prohibiting speculative activities [5]. Fundraising Management - The company has set up a fundraising management method to regulate the storage, use, and supervision of raised funds, ensuring they are used exclusively for designated projects and not for financial investments [6]. - Any changes in fundraising projects or surplus fund usage must go through board or shareholder meeting approval, with biannual progress checks and annual verification reports from accounting firms [6]. Shareholding Management - Borui Pharmaceutical has established a management system for shares held by directors and senior management, outlining restrictions on share transfers and trading periods, as well as disclosure requirements [7].

Group 1 - The core viewpoint of the article is that Zhejiang Zhenyuan has successfully managed its production and sales of histidine since its launch, aligning with market demand [2] Group 2 - The company has reported good production and sales conditions for histidine, indicating a positive response to market needs [2]

Core Viewpoint - *ST Changyao faces significant financial and legal challenges, including potential delisting due to continuous financial losses and allegations of falsifying financial reports [2][5][6]. Financial Performance - The company reported a negative net asset of -4.33 billion yuan for the fiscal year 2024, which may lead to delisting if the negative trend continues into 2025 [5]. - The audited net profits for 2022, 2023, and 2024 were -76.39 million yuan, -632 million yuan, and -569 million yuan respectively, indicating a consistent decline in financial performance [5]. Legal Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for inflating revenue and profits over three consecutive years, leading to a proposed fine of 10 million yuan for the company and 31 million yuan for 14 responsible individuals [6]. - A court ruling denied the company's restructuring application, citing a lack of feasibility, and declared bankruptcy for several subsidiaries [4]. Stock Market Impact - On December 30, the stock price dropped to 0.95 yuan per share, a decline of 19.49%, marking the first time the stock closed below 1 yuan, which could trigger delisting procedures [2][3]. - The stock has been placed under a delisting risk warning effective December 29, 2025, due to the ongoing financial and legal issues [5].

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice from the Beijing Drug Administration for its active pharmaceutical ingredient, Mirabegron, indicating successful compliance with the 2010 revised Good Manufacturing Practice standards [1] Group 1 - The inspection took place from December 11 to 15, 2023 [1] - The scope of the inspection covered the Mirabegron production line in the second workshop [1] - The inspection conclusion confirmed that the company met the relevant standards and appendix requirements [1]

Core Viewpoint - The announcement highlights a significant contract signed by the company's wholly-owned subsidiary, Ausino, which is expected to contribute positively to the company's revenue and market position in the pharmaceutical supply chain [1][2]. Group 1: Contract Details - The contract signed on May 22, 2023, involves a total amount of approximately $102 million (including tax), with an actual performance amount of about $20 million (approximately RMB 143.53 million) for the year 2025, representing 8.83% of the company's audited revenue for 2024 and 29.05% of customized products and services revenue [1]. - The actual performance amount for 2025 exceeds the procurement guidance of $12.15 million by 65.43%, showcasing the company's technical strength and market competitiveness [1]. Group 2: Financial Impact - The successful execution of this contract is expected to have a positive impact on the company's operating performance for 2025, enhancing its sustainability and brand influence while expanding its overseas market [2]. - In the first three quarters of 2025, the company achieved revenue of RMB 1.527 billion, a year-on-year increase of 21.95%, and a net profit attributable to the parent company of RMB 445 million, up 26.92% year-on-year [2]. Group 3: International Strategy - The company has positioned internationalization as a core strategy, leveraging its technological advantages and production capacity to accelerate global market penetration [2]. - The company has established a sales network covering Europe, Latin America, India, and Africa, with peptide raw materials exported to 22 countries, including the United States, Europe, and Canada [2]. - The excess performance of the significant contract further validates the company's capability in expanding its overseas business [2].

Group 1 - The company, Shengda Bio, has a range of vitamin products including biotin and folic acid [2] - For raw material supply, the company primarily procures folic acid production materials through purchasing methods [2] - The company adopts a centralized procurement model for bulk raw materials to ensure high quality and stability of supply [2]